Amicus Therapeutics wins the UK Prix Galien award for Innovative Product, marking the first time in the history of the awards that an orphan drug received this esteemed recognition.
Investors & Media ❯ Featured Coverage
Click Below to Sort Topics
John Crowley, Chairman and CEO of Amicus Therapeutics, was interviewed by Pompe Disease News sharing his personal experience with Pompe disease, Enzyme Replacement Therapy (ERT), and the optimistic future for the next-generation of ERT and gene therapy.
Amicus Chairman and CEO John Crowley sits down with Entrepreneur Weekly’s Alan Taylor to discuss his personal story with Pompe disease and how he is spearheading an entrepreneurial culture within the biotech industry.
Amicus Therapeutics and Dr. James Wilson with the UPenn Gene Therapy Program are awarded Deal of the Year for their collaboration to advance AAV gene therapy research for rare metabolic disorders.
Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics, is a passionate advocate and expert in a wide variety of issues affecting individuals with rare diseases and their families. She has more than 18 years of experience of strategic marketing, resource development and executive management in nonprofit healthcare and the rare disease patient community.
In the podcast she shares her experiences and perspectives on the impact of patient advocacy for patients and families living with rare diseases.
Globes, the leading financial newspaper in Israel, profiles John Crowley’s personal story and Amicus Therapeutics